Abstract:OBJECTIVE:To investigate the activity of a novel adjuvant consisting of dimethyldioctyldecyl ammonium bromide (DDA) and BCG polysaccharide nucleic acid (BCG-PSN).METHODS:BCG-PSN was extracted by hot-phenol method, and combined with DDA and Mycobacterium tuberculosis fusion antigen AMM (Ag85B-MPT64(190-198)-Mtb8.4) to formulate the Mycobacterium tuberculosis subunit vaccine. Mice were immunized subcutaneously with a 2-week interval between the immunizations (0.2 ml/dose), and humoral and cell-mediated immunity were detected by ELISA and ELISPOT respectively.RESULTS:With the stimulation of Ag85B in vitro, the number of antigen specific IFN-gamma producing spleen lymphocytes were 222 +/- 79, 259 +/- 85, 230 +/- 64 per million respectively in the mice immunized with AMM + DDA + BCG-PSN, AMM + DDA, and BCG. Spleen lymphocytes in these 3 groups produced higher levels of IFN-gamma compared to the groups with the adjuvant of IFA or BCG-PSN alone or without adjuvant upon stimulation with Ag85B (t = 2.923-7.118, P < 0.05). Furthermore, the adjuvant consisting of DDA and BCG-PSN increased the ratio of Ig(2a)/IgG1 than DDA alone (0.125 vs. 0.025). Combined with AMM, the adjuvant DDA and the one consisting of DDA and BCG-PSN induced higher level of immunity than incomplete Freund's adjuvant (IFA), NaCl, and BCG-PSN alone.CONCLUSION:Mycobacterium tuberculosis subunit vaccine AMM + DDA + BCG-PSN induced a strong Th1-type immune response, and DDA + BCG-PSN, especially DDA promoted the immune response of the M. tuberculosis subunit vaccine in mice.

Polyethylenimine modified nanoparticle adjuvant increases therapeutic efficacy of DNA vaccine Ag 85 A-ESAT-6-IL-21 in mice infected with Mycobacterium tuberculosis

Nanoparticle-based Adjuvant for Enhanced Protective Efficacy of DNA Vaccine Ag85A-ESAT-6-IL-21 Against Mycobacterium Tuberculosis Infection.

Cpg7909 Adjuvant Enhanced Immunogenicity Efficacy In Mice Immunized With Esat6-Ag85a Fusion Protein, But Does Not Confer Significant Protection Against Mycobacterium Tuberculosis Infection

Efficient Tuberculosis Treatment in Mice Using Chemotherapy and Immunotherapy with the Combined DNA Vaccine Encoding Ag85B, MPT-64 and MPT-83

DNA electroporation prime and protein boost strategy enhances humoral immunity of tuberculosis DNA vaccines in mice and non-human primates.

Combined DNA Vaccine Encapsulated in Microspheres Enhanced Protection Efficacy Against Mycobacterium Tuberculosis Infection of Mice

Protection of Mice with a Divalent Tuberculosis DNA Vaccine Encoding Antigens Ag85B and MPT64

Ag85A DNA Vaccination Boosting Enhances BCG Primed-Mice Anti-Tuberculosis T Cell Responses

Combined DNA Vaccines Formulated in DDA Enhance Protective Immunity Against Tuberculosis.

Immunogenicity and Protective Efficacy Study Using Combination of Four Tuberculosis Dna Vaccines

Heterologous prime-boost BCG with DNA vaccine expressing fusion antigens Rv2299c and Ag85A improves protective efficacy against Mycobacterium tuberculosis in mice

Boosting BCG-primed Mice with Chimeric DNA Vaccine HG856A Induces Potent Multifunctional T Cell Responses and Enhanced Protection Against Mycobacterium Tuberculosis

A Heterologous DNA Priming-Mycobacterium Bovis BCG Boosting Immunization Strategy Using Mycobacterial Hsp70, Hsp65, and Apa Antigens Improves Protection Against Tuberculosis in Mice.

Improved Humoral Immunity Against Tuberculosis Esat-6 Antigen By Chimeric Dna Prime And Protein Boost Strategy

Induction of strong immune response against a multicomponent antigen of Mycobacterium tuberculosis in BALB/c mice using PLGA and DOTAP adjuvant

Intranasal Immunization with a Recombinant Adenovirus Encoding Multi-Stage Antigens of Mycobacterium tuberculosis Preferentially Elicited CD8+ T Cell Immunity and Conferred a Superior Protection in the Lungs of Mice than Bacillus Calmette-Guerin

Coadministration of Interleukin 2 Plasmid Dna with Combined Dna Vaccines Significantly Enhances the Protective Efficacy Against Mycobacterium Tuberculosis

DDA enhanced immunogenicity and protection of combined DNA vaccine against Mycobacterium tuberculosis

Study on Immunogenicity and Protective Efficacy of Tetravalent Combination M-Tuberculosis Dna Vaccinea

Cationic pH-sensitive liposome-based subunit tuberculosis vaccine induces protection in mice challenged with Mycobacterium tuberculosis

[Dimo-Thylidioctyl Ammonium Bromide-Bcg Polysaccharide Nucleic Acid Adjuvant Enhanced the Immunogenicity of a Mycobacterium Tuberculosis Subunit Vaccine].